Viola Ventures Research
Investment Thesis
Viola Ventures is the early-stage venture arm of Viola Group, an Israeli multi-strategy investment house managing over $7B in assets across Viola Ventures, Viola Growth, Viola Credit, and Viola FinTech. Founded in 2000 by Shlomo Dovrat and Avi Zeevi, Viola Ventures has spent more than two decades backing Israeli and Israeli-related technology founders "from inception to growth." The firm positions itself as an "impactful partner to exceptional entrepreneurs disrupting fast-changing markets," emphasizing hands-on support from the ideation phase rather than passive capital.
Sector Focus
Viola Ventures concentrates on Fintech, Cybersecurity, Vertical AI, Enterprise AI, AI Infrastructure, Quantum, and Defense technology, per its own fund materials for the newest fund (Viola Ventures 7). Historically the portfolio has also spanned enterprise software, marketing technology (Contentsquare, Outbrain), travel and insurance (Faye), proptech/real estate marketplaces (Guesty), and health/biotech AI (Immunai) — reflecting a generalist, technology-first mandate anchored in Israel's deep-tech and enterprise software strengths.
Stage Focus
The firm invests at Pre-Seed, Seed, and Series A, and explicitly includes "incubation processes" for very early teams. Viola Ventures 7, its newest flagship vehicle, is expected to make approximately 20 new investments once fully active.
Check Size
Exact check sizes are not publicly disclosed. Given a $250M raise across Viola Ventures 7 and the Viola Conviction Fund I, and a target of ~20 new investments from the flagship fund, typical initial checks are estimated in the low-to-mid single-digit millions, consistent with Seed/Series A norms for a fund of this size.
Recent Activity
Viola Ventures announced the first dry close of Viola Ventures 7 Early-Stage Investment Fund alongside the Viola Conviction Fund I (a ~$100M secondary vehicle for doubling down on top portfolio performers), totaling $250M, in December 2025. The flagship fund becomes fully active in H1 2026, with new investments in the interim still flowing from Viola Ventures VI. Confirmed 2026 activity includes participation in Tenna Systems' $13.5M seed (February 2026, defense/spectrum intelligence), Lama AI's Series A (June 2026, AI lending infrastructure for banks), and Faye's $50M Series C (August 2026, AI-driven travel insurance claims).
Portfolio Highlights
Viola Ventures has backed more than 150 companies and points to 11 unicorn outcomes. Marquee names include ironSource (Nasdaq IPO, later acquired by Unity), Payoneer (Nasdaq via SPAC), Redis, Pagaya (Nasdaq IPO), Lightricks, Immunai, Contentsquare, Verbit.ai, Bringg, Guesty, and Outbrain (Nasdaq IPO). Earlier-generation exits include Actimize, RedBend, ECI, Optimal+, and Samanage.
Team
- Shlomo Dovrat — Co-Founder & Managing Partner
- Avi Zeevi — Co-Founder & General Partner; Chairman
- Omry Ben David — Managing Partner
- Zvika Orron — Managing Partner
- Alex Shmulovich — Partner
- Itzik Avidor — CFO, Viola Group; Partner, Viola Ventures
- Tal Abuloff — Principal
- Alon Cinamon — Principal
Decision Process
Viola Ventures operates as a partnership with multiple Managing Partners (Dovrat, Ben David, Orron) and General Partners actively involved in sourcing and decision-making, rather than a solo-GP or committee-only structure — consistent with a firm of its scale and history.
Founder Preferences
The firm markets itself on value-add beyond capital: market validation, co-founder matching, management-team building, pricing/business-model design, business development and design-partner introductions, and fundraising support — suggesting a preference for technical founders early enough in their journey (including pre-product) to benefit from that operational scaffolding.
Geographic Focus
Viola Ventures is Israel-centric — it explicitly backs "Israeli or Israeli-related" technology companies — while its portfolio companies frequently headquarter or expand into the US and, to a lesser extent, the UK and Europe as they scale (e.g., Contentsquare in France, Faye and Immunai in the US).